Filing Flows › Sarepta Therapeutics (SRPT) › Guidance & outlook
Sarepta Therapeutics (SRPT) guidance and outlook
Sarepta Therapeutics (SRPT) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue (segment) $1.2B–$1.3B for FY2026. Sarepta Therapeutics' 10-Q filed Nov 5, 2026 makes 24 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.2B–$1.3B | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- the possible impacts of the results of our MIS51ON trial of EXONDYS 51 and our ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45, including the timing and outcome of additional results, potential regulatory actions from the FDA, including directives to remove these products from the market or alter labels, patient demand for these products and changes to reimbursement and coverage by insurance companies,…
- our ability to maintain, and our plan to continue building out our distribution network in jurisdictions in which our products are approved or in which we are seeking to make our products available, commercially or through our early access programs ("EAP");
- our plan to expand our pipeline through internal research and development and through strategic transactions;
- our ability to enter into research, development or commercialization alliances with universities, hospitals, independent research centers, non-profit organizations, pharmaceutical and biotechnology companies and other entities for specific molecular targets or selected disease indications and our ability to selectively pursue opportunities to access certain intellectual property rights that complement our…
- We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.
- In November 2025, we announced topline results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of two of our PMO Products: AMONDYS 45 and VYONDYS 53.
- As of the date of this Quarterly Report, we anticipate a PDUFA target action date of February 28, 2027.
- We intend to discuss with the FDA the results of this study and a potential pathway forward to resume commercial dosing in the non-ambulatory population.
- We anticipate re-engaging with the agency on next steps for the program after we receive data from Cohort 8 of Study 9001-103 (ENDEAVOR).
- We shared early results from this trial in March 2026, and expect to share multiple ascending dose data in the fourth quarter of 2026.
- We shared early results from this trial in March 2026 and expect to share multiple ascending dose data in the fourth quarter of 2026.
- Additionally, we have evaluated and will continue to evaluate further relationships with additional suppliers as appropriate for specific products, taking into account production volume, logistics, business continuity and other routine business considerations.
Sarepta Therapeutics' latest quarter
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Sarepta Therapeutics raise or lower its guidance?
Sarepta Therapeutics (SRPT) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue (segment) $1.2B–$1.3B for FY2026.
What does Sarepta Therapeutics expect?
the possible impacts of the results of our MIS51ON trial of EXONDYS 51 and our ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45, including the timing and outcome of additional results, potential regulatory actions from the FDA, including directives to remove these products from the market or alter labels, patient demand for these products and changes to reimbursement and coverage by insurance companies,… our ability to maintain, and our plan to continue building out our distribution network in jurisdictions in which our products are approved or in which we are seeking to make our produ
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.